Furthermore, anti-CSPG4 IgE significantly prolonged the survival of patient-derived melanoma xenografts engrafted with autologous patient immune cells, showcasing the potency of CSPG4-specific IgE mAbs against CSPG4-expressing patient-derived melanomas. Here, CSPG4 is linked to melanoma.